- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02934893
A Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control
A Randomized, Controlled, Open-label, Multi-center Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control
The benefit of drug therapy to persons with diabetes has been well established in clinical trials in terms of reducing cardiovascular risk, microvascular complications and mortality. However, treatment adherence and treatment effectiveness continue to be challenges in diabetes management.
Rimidi Diabetes has developed software algorithms to simulate the effect of anti-diabetic medications on an individual's glucose profile, allowing the clinician and their patient to visualize the anticipated outcome of a medical intervention. Use of this technology should allow for more targeted decision-making by the clinician and should facilitate a shared decision-making process with the PwD who is now privy to the thought process behind their medical management.
The proposed study is designed to test whether adding a decision support capability (Diabetes+Me Rx) that allows for modeling the anticipated effect of medication adjustments leads to improved glycemic control and a perceived benefit by healthcare providers and PwDs.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Recruitment
- Recruitment of persons with diabetes through a community diabetes management center according to inclusion and exclusion criteria below.
- This is a three-armed study. Enrollees will be randomized to continue diabetes care with standard diabetes management in the Medication Management Clinic or the Intervention Group and compared to a matched cohort managed through their primary care physician (PCP) and standard of care.
- The Intervention Group will be standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me with a connected glucometer.
- Upon recruitment, PwD will be oriented to the Diabetes+Me application and instructed on how to complete a glucose profile and how to enter data into the application. Baseline hemoglobin A1C will be measured.
- Enrollees will complete a brief survey of satisfaction with their diabetes management.
Study visits
- The first study visit will be 2 weeks following enrollment.
- Weight, number of medications, number of medication titrations, the presence of insulin and blood pressure will be measured at each study visit. Frequency of hypoglycemia in the preceding week will be documented at each visit. Adherence to medical prescription to be documented at each visit.
- If the PwD has not entered data into Diabetes+Me this will be done at the beginning of each study visit.
- At the first study visit, the HCP will review the glucose profile from the previous week, identify areas where the PwD is not meeting targets and model adjustments to their medications to achieve the desired anticipated effect. If indicated, a new prescription will be issued and the PwD instructed to collect a new glucose profile the week preceding the next visit.
- The second study visit will occur 5 weeks following the initial visit. The HCP and PwD will review the glucose profile from the previous week, identify areas where the PwD is not meeting targets and model adjustments to their medications to achieve the desired anticipated effect. If indicated, a new prescription will be issued and the PwD instructed to collect a new glucose profile the week preceding the final visit.
The third and final study visit will occur 5 weeks following the second visit. The HCP and PwD will review the glucose profile from the previous week and identify if the PwD is meeting targets.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Physician diagnosis of type 1 or type 2 diabetes
- Glycated hemoglobin > 9% within 3 months
- Age 18-80
- Not currently managed by study clinicians
Exclusion Criteria:
- Pregnant
- Active substance abuse
- Severe hearing or visual impairment
- No internet or email access
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Intervention Group
Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
|
referral to medication management clinic from primary care
Use of software and medication modeling tool as add on to medication management standard of care
|
Comparatore attivo: Standard Diabetes Management
Patient in standard diabetes management in the Medication Management Clinic
|
referral to medication management clinic from primary care
|
Nessun intervento: Primary Care
Matched cohort managed through their primary care physician (PCP) and standard of care.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Hemoglobin A1C
Lasso di tempo: change from baseline to 12 weeks
|
change from baseline to 12 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of hypoglycemic events per week
Lasso di tempo: change from 1st week to twelfth week
|
Decrease in frequency of hypoglycemia (# events per week
|
change from 1st week to twelfth week
|
Blood pressure
Lasso di tempo: change from baseline to 12 weeks
|
increase in percentage of patients with blood pressure in normotensive range
|
change from baseline to 12 weeks
|
BMI
Lasso di tempo: change from baseline to 12 weeks
|
decrease in BMI
|
change from baseline to 12 weeks
|
Healthcare provider satisfaction
Lasso di tempo: through study completion, an average of 1 year
|
healthcare provider satisfaction based on scoring of questionnaire
|
through study completion, an average of 1 year
|
A1C target attainment
Lasso di tempo: at 12 weeks
|
time to A1c goal attainment
|
at 12 weeks
|
Medication titrations needed
Lasso di tempo: 12 weeks
|
number of medication titrations over 12 week period needed to reach A1c goal
|
12 weeks
|
Patient satisfaction questionnaire
Lasso di tempo: through patient study completion, an average of 12 weeks
|
questionnaire addresses satisfaction with care and knowledge of diabetes self-management
|
through patient study completion, an average of 12 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Michael Jardula, MD, Desert Oasis Healthcare
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RD-DOHC
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Medication Management Clinic
-
University of PittsburghRitiratoAderenza ai farmaci | Reazione avversa al farmaco | Non aderenza ai farmaciStati Uniti
-
University of North Carolina, Chapel HillMedical University of South Carolina; National Institute of Mental Health (NIMH) e altri collaboratoriCompletatoHIV/AIDS | Aderenza ai farmaci | HIV | Comportamento sessuale | Infezioni a trasmissione sessuale (non HIV o epatite)Stati Uniti
-
Corina Schuster-AmftNon ancora reclutamento
-
Ulf Dornseifer, MDCompletatoMicrocircolazione | Termoregolazione | Patta liberaGermania
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Hamilton Academic Health Sciences...CompletatoMalattia cardiovascolare | Diabete mellitoCanada
-
Children's Hospital Los AngelesUniversity of Southern California; Cedars-Sinai Medical CenterAttivo, non reclutante
-
University of OttawaCompletatoBurnout, Professionista | Stress, emotivo | ResilienzaCanada
-
Duke UniversityCompletatoCannabis | Uso di cannabisStati Uniti
-
George Washington UniversityTranscultural Psychosocial Organization NepalCompletato